Lanluma: PLLA, the V and X Versions, and Natural Results

Perhaps you like the idea of softening some age-related facial changes or adjusting your body contours without surgery, but do not want to wake up with a suddenly unfamiliar face. Lanluma is often discussed alongside “your own collagen” and “natural volume”. What does that mean? Lanluma is an injectable poly-L-lactic acid (PLLA) product in the collagen-biostimulator category. Unlike a gel that creates an immediate contour, its intended effect develops gradually through the tissue response. It is a medical intervention with restrictions and potential complications, not simply a skin-care treatment.

The question is not just “Do I want Lanluma?” but which area and concern you hope to address, which exact product version is offered, and whether gradual change and the difficulty of correcting an unwanted result suit you. Subtle changes that preserve your features are possible, not guaranteed. If you need an immediate, more adjustable result, another approach may fit better.

Lanluma V versus Lanluma X: why does the letter on the box matter?

Sinclair markets different PLLA presentations under the Lanluma name. On its official website, Lanluma V is positioned for selected facial areas, while Lanluma X addresses contour and tissue appearance in body areas including the buttocks, thighs and upper arms. This does not imply identical packaging, dilution volumes, protocols or permitted injection sites. Dose, vial count and injection plan must follow the current local instructions for the specific version in the country of treatment.

In a published Sinclair product brochure, both presentations are described as containing the same active material, PLLA, but different quantities of powder per vial: Lanluma V has 210 mg and Lanluma X has 630 mg. These are presentation sizes, not a personal injection dose or permission to use the larger vial in every area. Reconstitution, area-specific volume and authorised indications must be checked against the current local instructions rather than borrowed from a marketing chart.

Neither the shared ingredient “PLLA” nor CE marking makes all products interchangeable. Juvederm, for example, is a hyaluronic-acid filler range that behaves differently in tissue; Radiesse uses a different biostimulatory material. Even products in one category cannot simply be substituted using the same volume, injection depth or areas.

The manufacturer's abbreviated safety information specifically excludes injection in or near the eye area, lips, nose and forehead. These limits matter more than attractive advertising diagrams of a face. If an unusual site is offered, the practitioner should explain whether it complies with the local approved instructions—not just point to somebody else's video.

How does PLLA work, and why is the final result not visible on injection day?

Poly-L-lactic acid particles are placed in the tissue layers specified for the product. They provoke a local response associated with gradual collagen production; collagen is a protein that helps support skin and connective tissue. The material breaks down over time. None of this means your body will automatically create any shape you wish for. Product distribution, initial tissue thickness, anatomy, quantity and injection technique remain crucial.

Immediately after treatment, an area may appear fuller because of the liquid used to prepare the product and swelling. Some of this early volume then subsides. That is not necessarily the loss of the treatment effect: collagen stimulation develops later. The brand describes visible change beginning around weeks 4–6 and continuing over subsequent months. This is a manufacturer guideline, not a personal promise. Plan final assessment with the treating clinician after the planned treatment stage rather than relying on a next-day selfie.

The manufacturer commonly describes 2–3 sessions separated by 4–6 weeks and mentions PLLA-class results lasting up to 2 years. These figures are neither a mandatory schedule nor a guarantee for you: the treated area, formulation, local instructions, tissue characteristics and long-term data may differ. The clinician should justify the smallest proportionate intervention for your concern, not automatically prescribe “three standard vials”.

What makes a result look natural?

In advertising, “natural” sometimes only means that there is no abrupt change on day one. In reality it depends on keeping familiar facial or body proportions, avoiding excess bulk and achieving even distribution. Biostimulation involves waiting; you cannot fully preview the eventual volume on injection day. If the result becomes fuller than you wanted, correcting it may be more difficult than with some hyaluronic-acid fillers.

Thin skin, little subcutaneous fat, previous filler or existing asymmetry should all be discussed before product choice. A small post-market Lanluma study in selected body areas recorded firmness and nodules, including sites with thinner soft tissue. This cannot predict your personal outcome, but it shows why injection depth matters from the outset. For a tiny area requiring exact immediate contouring, a clinician might consider a different product—or recommend no added volume at all.

Buttock results also need careful descriptions. PLLA injections are not surgical lifting or fat transfer, and cannot create identical shapes in people with different anatomy. Significant loose skin, substantial volume loss after weight reduction or expectations of dramatic enlargement may make advertising promises especially unrealistic.

What happens at the appointment, and how visible is recovery?

First the clinician reviews your history and examines the area: previous injections, scars, cold sores or infections, tendency to develop lumps, medication and allergies. The exact commercial name, version, batch and expiry should be documented; planned injection depth and locations, anaesthesia and follow-up should be explained. The clinician may use a needle or a cannula—a thin instrument used within tissues—depending on the plan and training. Neither technique eliminates vascular risk.

You may feel needle pricks, pressure, fullness and local tenderness. Local anaesthesia may be used according to the clinician's plan; it reduces discomfort but cannot guarantee a pain-free procedure. Immediately afterwards there may be redness, swelling, small bruises or sensitivity, all varying individually. A small area covered by clothing may attract less notice than the face even if the medical reaction is similar.

Lanluma's website advises avoiding strenuous exercise, heat and sun for 24–48 hours, and describes the “rule of five” massage: 5 minutes, 5 times daily, for 5 days, with an additional instruction to continue aftercare until 2 weeks after the final session. Get unambiguous personal written instructions from your clinician, since technique, site and local version of the IFU matter. Do not vigorously massage an unusually painful, swollen or discoloured area before medical review.

Who should not receive Lanluma, and what warning signs must not be ignored?

The manufacturer's abbreviated contraindications include age under 18, pregnancy and breastfeeding, hypersensitivity to ingredients, autoimmune disease now or in the past, current systemic steroids or immunosuppressants, active infection or inflammation, certain skin and vascular problems, impaired healing or clotting and a history of severe anaphylactic reactions. These are manufacturer statements: the full locally applicable instructions must guide a clinician's assessment, not your own interpretation of a checklist. Never stop prescribed medicines to have injections.

Some reactions, such as short-term tenderness or bruises, are expected possibilities. Others need care: infection, persistent inflammation, hard nodules and granulomas. A granuloma is an inflammatory lump that may arise from tissue response to a material. Wider PLLA-class evidence and a 2026 expert consensus discuss different causes and treatments of nodules. Unlike hyaluronic-acid gel, PLLA cannot simply be dissolved by a routine hyaluronidase injection; management may require observation and specialist treatment.

Seek emergency medical care immediately for unusually severe or rapidly increasing pain, white, grey or blue skin near an injection, sudden visual disturbance, marked weakness, facial drooping or speech difficulty. These can indicate vascular injury. The FDA discusses these serious events for dermal fillers as a category, not as a Lanluma-specific frequency estimate. Fever, worsening redness, hot painful swelling or discharge from a puncture site require urgent assessment for possible infection.

How strong is the evidence for Lanluma itself?

Evidence exists for PLLA as a class, alongside some studies specifically of Lanluma. A prospective post-market Lanluma study published in 2024 involved 70 people and 99 sessions across five areas: neck, décolletage, upper arms, hands and thighs. Participants and researchers reported satisfaction; firmness and nodules occurred, with no serious adverse events in this small cohort. But the study was open-label, lacked a control group, lasted 9 months, and the authors declared manufacturer payments. It cannot predict individual outcomes, demonstrate superiority to another product or rule out rare complications.

A 2025 international consensus on body PLLA discusses its potential while stressing that many body-area claims rest largely on observational studies and case series. Results with PLLA-SCA or other brands are not automatically clinical trials of Lanluma. In particular, safety observations for hands or the neck should not be converted into promises of a particular buttock enlargement: areas, doses and clinical goals differ.

Lanluma's website reports CE marking for markets where the product is authorised, but explicitly says it is not approved for use in the United States and that indications vary by country. CE marking and manufacturer statements do not independently establish registration, legal distribution or availability in Armenia. Any specific offer in Yerevan requires checking the product documentation and local legal status before injection.

Lanluma, a hyaluronic-acid filler or something else: what should you ask?

A good consultation should answer specific questions. Is this Lanluma V or X, which local instructions apply and why this area? How are quantity and depth chosen? Were before-and-after photographs taken in comparable light and at comparable intervals? What is the plan for nodules, infection or vascular complications? Who provides follow-up and where? What costs are covered, including repeat visits and care if something goes wrong?

Do not consent until the explanations make sense and written informed consent is in place. Other people's early post-treatment photographs do not show the final contour; reviews rarely describe injection technique or length of follow-up. Needing time to compare options without pressure is a valid reason to postpone.